Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials

Rifaximin in the treatment of recurrentClostridium difficileinfection

(2012) E. Mattila et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months

(2012) P. Meyrat et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome

(2012) Eric Shah et al.   AMERICAN JOURNAL OF MEDICINE

Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB, and Activity of Phe-Arg- -Naphthylamide-Inhibitable Efflux Pumps

(2012) V. Kothary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VivoSelection of Rifamycin-Resistant Clostridium difficile during Rifaximin Therapy

(2012) Robert J. Carman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Current State of Clostridium difficile Treatment Options

(2012) A. A. Venugopal et al.   CLINICAL INFECTIOUS DISEASES

Current Status of Clostridium difficile Infection Epidemiology

(2012) F. C. Lessa et al.   CLINICAL INFECTIOUS DISEASES

645 RATES OF COMMONLY OCCURING INFECTIONS IN CIRRHOSIS PATIENTS REMAIN STABLE DURING LONG-TERM RIFAXIMIN TREATMENT

(2012) A. Sanyal et al.   JOURNAL OF HEPATOLOGY

The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

(2011) Stacy B Menees et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease

(2011) Cosimo Prantera et al.   GASTROENTEROLOGY

A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection

(2011) K. W. Garey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antibiotic Therapy for the Irritable Bowel Syndrome

(2011) Jan Tack   NEW ENGLAND JOURNAL OF MEDICINE

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

(2011) Mark Pimentel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rifaximin Is Effective for the Treatment ofClostridium difficile—Associated Diarrhea: Results of an Open-Label Pilot Study

(2011) David T. Rubin et al.   Gastroenterology Research and Practice

Clostridium difficileinfection: update on emerging antibiotic treatment options and antibiotic resistance

(2010) Dhara Shah et al.   Expert Review of Anti-Infective Therapy

Rifaximin Treatment in Hepatic Encephalopathy

(2010) Nathan M. Bass et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial

(2010) P. Patrick Basu et al.   Therapeutic Advances in Gastroenterology

Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: Experience with Rifaximin

(2009) Sergio Peralta et al.   WORLD JOURNAL OF GASTROENTEROLOGY

T1390 Rifaximin for the Treatment of Diarrhea-Associated Irritable Bowel Syndrome: Short Term Treatment Leading to Long Term Sustained Response

(2008) Anthony Lembo et al.   GASTROENTEROLOGY